腺素A1和A3受体:显著的心脏保护作用
Bruce T Liang1, Douglas Stewart1, Kenneth A Jacobson2
1Department of Medicine, Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
Drug development research
|January 1, 2025
概括
氨酸在缺血期间保护心脏,但其机制尚不清楚. 最近对腺受体连接体和心脏模型的研究揭示了其心脏保护信号通路.
科学领域:
- 心血管生理学心血管生理学
- 分子药理学分子药理学
- 心脏缺血症的心脏缺血症是什么
背景情况:
- 腺素在心肌缺血期间释放,提供心脏保护.
- 目前尚不完全了解氨酸抗胰岛症作用的确切机制.
研究的目的:
- 审查最近关于腺对心脏作用的细胞和分子机制的进展.
- 要突出新型腺素受体连接体的心脏保护作用.
主要方法:
- 关于心血管系统中腺信号传递的最新科学文献的综述.
- 从研究心脏腺素作用的模型系统分析数据.
- 检查新型腺受体连接体及其药理性质.
主要成果:
- 在腺受体连接体化学和药理学方面的进展提供了新的见解.
- 模型系统已经阐明了从受体激活到心脏保护的信号级联.
- 新型配体显示出显著的心脏保护作用.
结论:
- 了解腺的细胞和分子机制对于开发新的心脏保护策略至关重要.
- 新型腺素连接体代表了对心肌缺血的有前途的治疗途径.
更多相关视频
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
502
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
502
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
636
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
636
Adrenergic Agonists: Therapeutic Uses
673
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
673
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
744
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
744
Adrenergic Receptors: β Subtype
1.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.4K


